PERSON
J&J’s Nipocalimab Shows Promise in Sjögren’s Disease with Significant Phase 2 Results
nipocalimab, Sjögren’s disease, Johnson & Johnson, Phase 2 study, autoimmune disease, FcRn inhibitor
Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery
Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.
Ipsen and Genfit Secure FDA Approval for Iqirvo, a Breakthrough Treatment for Primary Biliary Cholangitis
Ipsen, Genfit, Iqirvo, FDA approval, primary biliary cholangitis, liver disease, Intercept, Ocaliva
Lilly’s Tirzepatide Wins NICE Endorsement for Obesity Treatment with BMI and Weight Loss Conditions
Lilly, tirzepatide, NICE endorsement, obesity treatment, BMI, weight loss, Zepbound, Mounjaro, GLP-1 receptor agonist
GSK Acquires Oligonucleotide Partner Elsie for Up to $50 Million
GSK, Elsie Biotechnologies, oligonucleotide platform, acquisition, biotech, pharmaceuticals
Lilly Initiates Search for New CFO Following Anat Ashkenazi’s Departure to Alphabet
Anat Ashkenazi, CFO, Eli Lilly, Alphabet, Google, Ruth Porat, Sundar Pichai, Financial Leadership, Biopharma, Tech Industry
ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition
ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing
Amarin Names New CEO Aaron Berg Following Patrick Holt’s Resignation
Amarin, CEO, Patrick Holt, Aaron Berg, Resignation, Leadership Transition
Brandon Capital Raises $180M Fund to Boost Australia and New Zealand Biotechs
Brandon Capital, biotechs, Australia, New Zealand, life sciences, venture capital, fund, startups, scale-ups
FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###
Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology